Meropenem Clinical Pharmacokinetics

Clinical Pharmacokinetics

Volumn 28, Issue 4, 1995, Pages 275-286

  Mouton, Johan W ^a   van den Anker, John N ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; IMIPENEM; MEROPENEM; PROBENECID;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; CEREBROSPINAL FLUID; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG PENETRATION; DRUG STABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; NEPHROTOXICITY; NEUROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

AGED; CHILD; HUMAN; KIDNEY DISEASES; POSTOPERATIVE CARE; THIENAMYCINS;

EID: 0028943898     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199528040-00002     Document Type: Review

References (69)

1. The carbapenems: new broad spectrum β-lactam antibiotics
2. In vitro and pharmacokinetic properties of the carbapenems
3. Comparative in vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum-β-lactamases
4. Multicenter in-vitro evaluation of SM-7338, a new carbapenem
5. Meropenem: activity against Gram-negative bacteria and interactions with β-lactamases
6. Interactions of meropenem with class 1 chromosomal β-lactamases
7. Antibacterial activity of meropenem against Gram-negative bacteria with a permeability defect and against staphylococci
8. Diffusion of β-lactam antibiotics through liposome membranes reconstituted from purified outer membranes of Pseudomonas aeruginosa
9. Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and its release from these proteins and morphological changes
10. Affinities of SM-7338 for penicillin-binding proteins and its release from these proteins in Staphylococcus aureus
11. Transferable imipenem resistance in Pseudomonas aeruginosa
12. Molecular characterization of an enterobacterial metallo β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance
13. Rapid identification of metallo- and serine β-lactamases
14. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa
15. Meropenem pharmacokinetics and penetration into inflammatory exudate
16. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease
17. The pharmacokinetics of meropenem in volunteers
18. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment
19. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem
20. The disposition and metabolism of meropenem in laboratory animals and man
21. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion
22. Basic and clinical studies of meropenem in urology
23. Clinical phase I study of meropenem
24. A problem in the interpretation of beta-lactam antibiotic levels in tissues
25. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning
26. Antibiotic assays in muscle: are conventional tissue levels misleading as indicator of the antibacterial activity?
27. Pharmacokinetic and clinical studies on meropenem in plastic and reconstructive surgery
28. Concentration of meropenem in tissues and clinical efficacy in otorhinolaryngology
29. Bacteriological, pharmacokinetic and clinical studies of meropenem in otorhinolaryngological infections
30. Basic and clinical studies on meropenem in otorhinolaryngological infections
31. Basic and clinical studies on meropenem in ophthalmology
32. Basic and clinical studies of meropenem in urinary tract infection
33. Laboratory and clinical studies of meropenem in respiratory tract infection
34. Distribution of meropenem in human biliary tract
35. A study of the penetration of meropenem into bile using endoscopic retrograde cholangiography
36. Concentration of meropenem in serum and in bronchial secretions in patients undergoing fibreoptic bronchoscopy
37. High-dose meropenem in meningitis due to Pseudomonas aeruginosa
38. Metabolism of thienamycin and related carbapenem antibiotics by renal dipeptidase: dehydropeptidase-1
39. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males
40. Pharmacokinetics of Meropenem in subjects with various degrees of renal impairment
41. Pharmacokinetics of meropenem in patients with intra-abdominal infections
42. Basic and clinical evaluation of meropenem
43. Pharmacokinetic study on meropenem
44. Clinical pharmacology and efficacy of meropenem
45. Effect of renal function on the pharmacokinetics of meropenem
46. Pharmacokinetic and clinical studies on meropenem
47. Clinical and pharmacokinetic evaluation of meropenem and its effect on fecal flora in children
48. Basic and clinical study of meropenem in pediatric field
49. Laboratory and clinical evaluation of meropenem in pediatric field
50. Studies of meropenem in pediatric infections
51. Clinical evaluation of a new carbapenem, meropenem, in infants and children
52. Pharmacokinetics and clinical studies with meropenem in the pediatric field
53. Pharmacokinetic, bacteriological and clinical studies on meropenem in children
54. Penetration of meropenem into cerebrospinal fluid of patients with inflamed meninges
55. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men
56. Basic and clinical study on meropenem
57. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients
58. Continuous infusion of beta-lactam antibiotics
59. Kinetics of antimicrobial activity
60. Role for dual individualization with cefmenoxime
61. Postantibiotic effect of β-lactam antibiotics 1992 on gram-negative bacteria in relation to morphology, initial killing and MIC
62. Retain intermittent dosing of carbapenems
63. Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms
64. Retain intermittent dosing of carbapenems
65. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone
66. Drug clearance by continuous arteriovenous hemodiafiltration (CAVHD)